NovelMed is a cutting-edge clinical-stage biotech company located in Ohio and is focused on developing breakthrough treatments for rare diseases. As a privately-held biotechnology company, NovelMed specializes in the development of novel biologics for both orphan and non-orphan diseases. They have a specific focus on blocking certain parts of the immune system that are involved in the disease process.

NovelMed has an impressive portfolio of neutralizing monoclonal antibodies, including Anti-Bb, Anti-P, and Anti-C3b, which they use to target chronic diseases with a large market potential and unmet medical need. They utilize an innovative research and development strategy that enables them to identify the best-fit candidates for further development. The company has achieved remarkable success in advancing multiple antibodies with a superior mechanism of action compared to other pharmaceutical companies.

Their therapeutic antibodies have shown a higher level of selectivity, efficacy, and safety, particularly in targeting the alternative complement pathway. NovelMed is currently advancing their preclinical and clinical studies and plans to start Phase II trials for several orphan and non-orphan indications. Their goal is to provide first-in-class diagnostics and novel drugs to treat rare diseases, thereby redefining what is humanly possible in the field of medicine